Evidence map›Paper›PMID 34836270›Full record

ArticleNutrients2021

Beneficial Effects of Slow-Release Large Neutral Amino Acids after a Phenylalanine Oral Load in Patients with Phenylketonuria.

Iris Scala, Daniela Concolino, Anna Nastasi, Giulia Esposito, Daniela Crisci, Simona Sestito, Stefania Ferraro, Lucia Albano, Margherita Ruoppolo, Giancarlo Parenti and 1 more

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Current state of the treatment landscape of phenylketonuria.Orphanet journal of rare diseases · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Iris ScalaDepartment of Maternal and Child Health, Federico II University Hospital, 80131 Naples, Italy.ORCID 0000-0003-2725-437X
Daniela ConcolinoPediatric Unit, Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0003-1223-7358
Anna NastasiPhysiology Nutrition Unit, Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy.
Giulia EspositoDepartment of Translational Medical Science, Section of Pediatrics, Federico II University, 80131 Naples, Italy.
Daniela CrisciCEINGE Biotecnologie Avanzate Scarl, 80131 Naples, Italy.
Simona SestitoPediatric Unit, Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.
Stefania FerraroPediatric Unit, Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.
Lucia AlbanoCEINGE Biotecnologie Avanzate Scarl, 80131 Naples, Italy.
Margherita RuoppoloCEINGE Biotecnologie Avanzate Scarl, 80131 Naples, Italy.ORCID 0000-0002-7364-0602
Giancarlo ParentiDepartment of Translational Medical Science, Section of Pediatrics, Federico II University, 80131 Naples, Italy.
Pietro StrisciuglioDepartment of Translational Medical Science, Section of Pediatrics, Federico II University, 80131 Naples, Italy.
Federico II University Hospital · ITMagna Graecia University · ITCeinge Biotecnologie Avanzate (Italy) · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mainstay of phenylketonuria treatment is a low protein diet, supplemented with phenylalanine (Phe)-free protein substitutes and micronutrients. Adhering to this diet is challenging, and even patients with good metabolic control who follow the dietary prescriptions in everyday life ignore the recommendations occasionally. The present study explores the ability of slow-release large neutral amino acids (srLNAAs) to prevent Phe increase following a Phe dietary load. Fourteen phenylketonuric patients aged ≥13 years were enrolled in a 6-week protocol. Oral acute Phe loads of 250 and 500 mg were added to the evening meal together with srLNAAs (0.5 gr/kg). Phe and tyrosine were dosed before dinner, 2h-after dinner, and after the overnight fast. After oral Phe loads, mean plasma Phe remained stable and below 600 µmol/L. No Phe peaks were registered. Tyrosine levels significantly increased, and Phe/Tyrosine ratio decreased. No adverse events were registered. In conclusion, a single oral administration of srLNAAs at the dose of 0.5 gr/kg is effective in maintaining stable plasma Phe during acute oral loads with Phe-containing food and may be added to the dietetic scheme in situations in which patients with generally good adherence to diet foresee a higher than prescribed Phe intake due to their commitments.

Indexed as

Dietary SupplementsAdolescentAdultAmino AcidsAmino Acids, NeutralDietFemaleHumansItalyMaleMicronutrientsPhenylalaninePhenylketonuriasTyrosineYoung AdultAmino AcidsAmino Acids, NeutralMicronutrientsPhenylalanineTyrosinelarge neutral amino acidsLNAAPhephenylalaninephenylalanine loadphenylketonuriaPKUsrLNAATyrtyrosine

Identifiers

PMID34836270
PMCPMC8618154
OpenAlexW3212630965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.